Alpha Tau Treats First Brain Cancer Patient Outside US, Expanding Alpha DaRT Reach
Summary
Alpha Tau Medical successfully treated its first glioblastoma patient outside the U.S. with its Alpha DaRT therapy at Hadassah University Medical Center, completing the procedure safely. This follows a 6-K filing yesterday announcing the event and continues a strong run of positive clinical and partnership milestones for the company. The international expansion into brain cancer is significant, demonstrating the therapy's broader applicability for a highly aggressive disease with limited treatment options. This adds to Alpha Tau's growing global clinical footprint.
At the time of this announcement, DRTS was trading at $10.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $900.3M. The 52-week trading range was $2.87 to $11.62. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: FinanceWire.